Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
<p>Abstract</p> <p>Background</p> <p>This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU)...
Main Authors: | Cals Laurent, Husseini Fares, Brezault Catherine, Peeters Marc, Van Laethem Jean-Luc, Raoul Jean-Luc, Nippgen Johannes, Loos Anja-Helena, Rougier Philippe |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-04-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/9/112 |
Similar Items
-
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
by: Höhler Thomas, et al.
Published: (2004-07-01) -
A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
by: Lise Verbruggen, et al.
Published: (2023-08-01) -
FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial
by: Xiaowei Zhang, et al.
Published: (2022-01-01) -
Durable complete response in a patient with metastatic left‐sided colon cancer treated with 5‐fluorouracil, folinic acid, and irinotecan (FOLFIRI) and panitumumab: A case report
by: Esther Kim, et al.
Published: (2019-07-01) -
A Case of Metastatic Urachal Carcinoma Treated With FOLFIRI (irinotecan and 5-Fluorouracil/leucovorin) Plus Bevacizumab
by: Tomohiro Kanamaru, et al.
Published: (2015-03-01)